Genetic Technologies Limited (ASX:GTG, NASDAQ:GENE, OTC:GNTLF) has begun testing operations in the United States, offering genomics-based tests in health, wellness and serious disease performed by Gene by Gene, a premier specialty genetic laboratory based in Houston, Texas.
GTG’s geneType multi-patented, clinically validated tests will be performed by a state-of-the-art, highly accredited laboratory (CLIA, CAP, AABB and CDPH licensed) with the ability to process up to 25,000 tests per month, greatly increasing the company’s operational capacity in North America.
The move synergises with GTG’s recent distribution agreement with health and wellness technology leader Stay Healthy, Inc., offering an opportunity for rapid growth across the North American market.
Personalised, actionable healthcare
“As personalised medicine and health-consciousness continue to trend upwards, we are confident that the uniquely integrated, highly accurate geneType test will continue to meet the rising demand for personalised, actionable health information,” Genetic Technologies CEO Simon Morriss said.
“Our collaboration with Gene by Gene and Stayhealthy solidifies the infrastructure needed to deliver that information so that individuals and healthcare providers in North America can take control of their health.”
Stayhealthy has access to markets involving employee health benefits and online pharmacy channels across the US and Canada.
In 2023, Stayhealthy launched a Direct to Consumer (DTC) online discount pharmacy card and website with access of up to 1.5 million users and a Business to Business to Consumer (B2B2C) model.
The company has a database of more than 200 million US email addresses, offering a large market to promote geneType’s portfolio of personalised health risk assessments across North America.
“Our mission at Stayhealthy is to empower individuals to take control of their health,” Stayhealthy CEO John Collins said.
“GeneType’s non-invasive, predictive genetic testing not only complements our mission; it also integrates perfectly with our technology.”